EGFR and neoplasm: Combinations of different, non-competitive antibodies targeting the EGFR (including cetuximab and panitumumab, but not together in the same combination since they compete with each other) inhibited tumor growth in triple-negative breast cancer models by promoting a more efficient down-regulation and degradation of the receptor (Ferraro et al., 2013).